Fig. 5.

TC-2153 prevents PCP-induced decrease of BDNF expression during memory consolidation and memory deficits in the novel object recognition (NOR) test. a Male C57BL/6 mice (4–6-month old) were pretreated with vehicle (Veh) or TC-2153 (TC, 10 mg/kg, i.p.) followed by vehicle or subchronic PCP administration (5 mg/kg, i.p. twice daily) for 5 days, followed by a 1-week drug-free break. A discrimination index was used to evaluate memory retention in different treatment groups. b A second cohort of mice was sacrificed 9 h post-training in the NOR test. BDNF and STEP₆₁ levels were measured in synaptosomal fraction (P2) from hippocampus. Data were expressed as mean ± SEM. One-way ANOVA with post hoc Bonferroni’s test was performed to determine statistical significance (*p < 0.05, n = 9 C57BL/6 mice per group for a; n = 6 C57BL/6 mice per group for b)